Cargando…
P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429007/ http://dx.doi.org/10.1097/01.HS9.0000847364.49527.45 |
| _version_ | 1784779297371717632 |
|---|---|
| author | Cheah, C. Y. Bartlett, N. L. Assouline, S. Schuster, S. J. Seog Kim, W. Shadman, M. Isufi, I. Yin, S. Doral, M. Y. Sit, J. Chen, V. Huang, H. Zhou, M. Wei, M. C. Budde, L. E. |
| author_facet | Cheah, C. Y. Bartlett, N. L. Assouline, S. Schuster, S. J. Seog Kim, W. Shadman, M. Isufi, I. Yin, S. Doral, M. Y. Sit, J. Chen, V. Huang, H. Zhou, M. Wei, M. C. Budde, L. E. |
| author_sort | Cheah, C. Y. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429007 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94290072022-08-31 P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA Cheah, C. Y. Bartlett, N. L. Assouline, S. Schuster, S. J. Seog Kim, W. Shadman, M. Isufi, I. Yin, S. Doral, M. Y. Sit, J. Chen, V. Huang, H. Zhou, M. Wei, M. C. Budde, L. E. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429007/ http://dx.doi.org/10.1097/01.HS9.0000847364.49527.45 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Cheah, C. Y. Bartlett, N. L. Assouline, S. Schuster, S. J. Seog Kim, W. Shadman, M. Isufi, I. Yin, S. Doral, M. Y. Sit, J. Chen, V. Huang, H. Zhou, M. Wei, M. C. Budde, L. E. P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA |
| title | P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA |
| title_full | P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA |
| title_fullStr | P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA |
| title_full_unstemmed | P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA |
| title_short | P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA |
| title_sort | p1124: mosunetuzumab retreatment is effective and well-tolerated in patients with relapsed or refractory b-cell non-hodgkin lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429007/ http://dx.doi.org/10.1097/01.HS9.0000847364.49527.45 |
| work_keys_str_mv | AT cheahcy p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT bartlettnl p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT assoulines p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT schustersj p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT seogkimw p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT shadmanm p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT isufii p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT yins p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT doralmy p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT sitj p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT chenv p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT huangh p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT zhoum p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT weimc p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma AT buddele p1124mosunetuzumabretreatmentiseffectiveandwelltoleratedinpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma |